Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02959996 · ClinicalTrials.gov registry record · Phase 2
Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT02959996: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02959996 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 80 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02959996, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is a randomized controlled trial to test whether the use of liposomal bupivacaine at the time of cesarean delivery may decrease post-operative pain scores.
Interventions
- DRUG Placebo
- DRUG Liposomal bupivacaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2017-03-08 |
| Est. Completion | 2017-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02959996
The ClinicalTrials.gov registry entry for NCT02959996 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02959996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02959996 about?
NCT02959996 is a clinical study titled "Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain". This is a randomized controlled trial to test whether the use of liposomal bupivacaine at the time of cesarean delivery may decrease post-operative pain scores.
What is the current status of trial NCT02959996?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2017-03-08. Estimated completion is 2017-11-03.
What interventions are being tested in trial NCT02959996?
The interventions under investigation include: Placebo (DRUG), Liposomal bupivacaine (DRUG).
Who is sponsoring clinical trial NCT02959996?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.